Signet Investment Advisory Group, Inc. Salarius Pharmaceuticals, Inc. Transaction History

Signet Investment Advisory Group, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 11, 2021	SELL	$1.0 - $3.0 $10,000 - $30,000	-10,000 Closed	0 $0
Q4 2020 Feb 05, 2021	BUY	$0.65 - $1.34 $6,500 - $13,400	10,000 New	10,000 $9,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $5.1M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Signet Investment Advisory Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Signet Investment Advisory Group, Inc. with notifications on news.